Total Valuation
AnaptysBio has a market cap or net worth of €1.34B. The enterprise value is €2.11K.
Market Cap€1.34B
Enterprise Value€2.11K
Share Statistics
AnaptysBio has 29,895,245 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding29,895,245
Owned by Insiders2.26%
Owned by Institutions51.76%
Financial Efficiency
AnaptysBio’s return on equity (ROE) is -0.36 and return on invested capital (ROIC) is 14.61%.
Return on Equity (ROE)-0.36
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)14.61%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee2.26M
Profits Per Employee477.06K
Employee Count104
Asset Turnover0.64
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of AnaptysBio is 7.5. AnaptysBio’s PEG ratio is 0.77.
PE Ratio7.5
PS Ratio3.83
PB Ratio24.14
Price to Fair Value24.14
Price to FCF45.80
Price to Operating Cash Flow81.86
PEG Ratio0.77
Income Statement
In the last 12 months, AnaptysBio had revenue of 234.60M and earned -13.23M in profits. Earnings per share was -0.46.
Revenue234.60M
Gross Profit232.18M
Operating Income47.90M
Pretax Income-13.07M
Net Income-13.23M
EBITDA69.25M
Earnings Per Share (EPS)-0.46
Cash Flow
In the last 12 months, operating cash flow was 18.08M and capital expenditures -13.00K, giving a free cash flow of 18.07M billion.
Operating Cash Flow18.08M
Free Cash Flow18.07M
Free Cash Flow per Share0.60
Dividends & Yields
AnaptysBio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.39
52-Week Price Change161.56%
50-Day Moving Average47.87
200-Day Moving Average41.56
Relative Strength Index (RSI)34.66
Average Volume (3m)10.00
Important Dates
AnaptysBio upcoming earnings date is Nov 10, 2026, Before Open (Confirmed).
Last Earnings DateSep 21, 2026
Next Earnings DateNov 10, 2026
Ex-Dividend Date―
Financial Position
AnaptysBio as a current ratio of 9.07, with Debt / Equity ratio of 2546.89%
Current Ratio9.07
Quick Ratio9.07
Debt to Market Cap0.01
Net Debt to EBITDA-3.24
Interest Coverage Ratio0.60
Taxes
In the past 12 months, AnaptysBio has paid 164.00K in taxes.
Income Tax164.00K
Effective Tax Rate-0.01
Enterprise Valuation
AnaptysBio EV to EBITDA ratio is 9.73, with an EV/FCF ratio of 34.37.
EV to Sales2.87
EV to EBITDA9.73
EV to Free Cash Flow34.37
EV to Operating Cash Flow34.22
Balance Sheet
AnaptysBio has €164.14M in cash and marketable securities with €269.59M in debt, giving a net cash position of -€105.44M billion.
Cash & Marketable Securities€164.14M
Total Debt€269.59M
Net Cash-€105.44M
Net Cash Per Share-€3.53
Tangible Book Value Per Share€1.34
Margins
Gross margin is 109.91%, with operating margin of 20.42%, and net profit margin of -5.64%.
Gross Margin109.91%
Operating Margin20.42%
Pretax Margin-5.57%
Net Profit Margin-5.64%
EBITDA Margin29.52%
EBIT Margin28.48%
Analyst Forecast
The average price target for AnaptysBio is €70.58, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€70.58
Price Target Upside42.03% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast79.13%
EPS Growth Forecast―